27 January 2017

To: Recipients of M100, 27th ed.

From: Jennifer K. Adams, MT(ASCP), MSHA

Subject: Footnote Corrections and Additions in Tables 4A and 5A, Correction in Table 5D, and Update in Glossary II

This notification is to inform you of footnote labeling errors and the addition of new footnotes in Tables 4A and 5A, a correction in Table 5D, and an update to Glossary II in CLSI document M100, 27th ed., Performance Standards for Antimicrobial Susceptibility Testing.

The details of the changes are below.

“Cefepime-tazobactam (1:1)” has been revised throughout the document to read “cefepime-tazobactam.” The “(1:1)” ratio designation has been deleted; the affected pages are: xvii, xviii, 144, 147, 162, 165, 168, 218, 236, 240. Footnotes have been added to Tables 4A and 5A to clarify the change.

Table 4A:

- The column heading for Klebsiella pneumoniae ATCC® 700603 on the first page of Table 4A has two footnotes (b and d) associated with it; however, the footnote designations are missing on subsequent Table 4A pages (ie, Table 4A [Continued]). The footnote designations have been added to the column headings on the subsequent pages. Similar edits were made to the Escherichia coli ATCC® 25922 and Escherichia coli ATCC® 35218 column headings (ie, edits to ensure all footnotes that appear in the headings on the first page of Table 4A also appear in the headings on subsequent pages).

- Footnote designations are missing from the QC ranges in the Klebsiella pneumoniae ATCC® 700603 column for cefepime-tazobactam and ceftolozane-tazobactam. Footnote “d” has been added to the QC range for each agent.

- To clarify the disk diffusion QC ranges for reporting cefepime-tazobactam, a new footnote (r) was added that reads: “Cefepime-tazobactam (30/20-µg) disk diffusion QC ranges are for use with the cefepime-tazobactam high proportion (1:1 ratio) dosing regimen.”

The Table 4A changes described above are highlighted in the table excerpt below.
Table 4A. Disk Diffusion: Quality Control Ranges for Nonfastidious Organisms (Unsupplemented Mueller-Hinton Medium)

<table>
<thead>
<tr>
<th>Antimicrobial Agent</th>
<th>Disk Content</th>
<th>Disk Diffusion QC Ranges (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Escherichia coli ATCC® 25922</td>
</tr>
</tbody>
</table>

Abbreviations: ATCC®, American Type Culture Collection; QC, quality control.

Footnotes

d. *K. pneumoniae* ATCC® 700603 must be used for routine QC of cefepime-tazobactam, ceftaroline-avibactam, ceftazidime-avibactam, and aztreonam-avibactam. Either *K. pneumoniae* ATCC® 700603 or *E. coli* ATCC® 35218 can be used for routine QC of ceftolozane-tazobactam.

r. Cefepime-tazobactam (30/20-µg) disk diffusion QC ranges are for use with the cefepime-tazobactam high proportion (1:1 ratio) dosing regimen.

Table 5A:

- The column heading for *Klebsiella pneumoniae* ATCC® 700603 on the first page of Table 5A has two footnotes (b and g) associated with it; however, the footnote designations are missing on subsequent Table 5A pages (ie, Table 5A [Continued]). The footnote designations have been added to the column headings on the subsequent pages.

- In the cefepime-tazobactam row, footnotes “e” and “g” are attached to the agent name; however, only footnote “e” should be associated with the agent name. Footnote “g” should only be attached to the QC range for cefepime-tazobactam and *Klebsiella pneumoniae* ATCC® 700603. Footnote “g” has been moved to the QC range for *Klebsiella pneumoniae* ATCC® 700603.

- In the meropenem-vaborbactam row, the QC ranges are listed incorrectly. QC ranges for each organism have been corrected as follows:
  - *Staphylococcus aureus* ATCC® 29213: Range changed from 0.03-0.12 to 0.03/8-0.12/8.
  - *Escherichia coli* ATCC® 25922: Range changed from 0.008-0.06 to 0.008/8-0.06/8.
  - *Pseudomonas aeruginosa* ATCC® 27853: Range changed from 0.12-1 to 0.12/8-1/8.
  - *Escherichia coli* ATCC® 35218: Range changed from 0.008-0.06 to 0.008/8-0.06/8.
  - *Klebsiella pneumoniae* ATCC® 700603: Range changed from 0.015-0.06 to 0.015/8-0.06/8.
Table 5A (Continued):

- In the Table 5A footnote list, there are two footnotes designated as “t” and two footnotes designated as “u.”
  - The footnote stating “QC range for *S. aureus* ATCC® 25923 with tedizolid is 0.12–0.5 µg/mL; this strain exhibits less trailing and MIC end points are easier to interpret. *S. aureus* ATCC® 25923 is considered a supplemental QC strain and not required for routine QC of tedizolid MIC tests” has been redesignated as footnote “v” and reordered alphabetically.
  - The footnote stating “For QC organisms for vancomycin screen test for enterococci, see Table 3G” has been redesignated as footnote “w” and reordered alphabetically.
  - As a result of the redesignation of the above footnotes as “v” and “w,” the footnote associated with tedizolid has been changed to “v” and the footnote associated with vancomycin has been changed to “w.”

- For consistency with the edits made to the QC ranges in the meropenem-vaborbactam row, footnote “t” has been revised to read, “QC range for *K. pneumoniae* ATCC® BAA-1705™ with meropenem-vaborbactam is 0.015/8-0.06/8 µg/mL.”

- To clarify the broth dilution QC ranges for reporting cefepime-tazobactam, a new footnote (x) was added that reads: “Cefepime-tazobactam (fixed 8 µg/mL) MIC QC ranges are for use with the cefepime-tazobactam high proportion (1:1 ratio) dosing regimen.”

The Table 5A changes described above are highlighted in the table excerpt below.

### Table 5A. MIC: Quality Control Ranges (µg/mL) for Nonfastidious Organisms (Unsupplemented Mueller-Hinton Medium [Cation-Adjusted if Broth])

<table>
<thead>
<tr>
<th>Antimicrobial Agent</th>
<th><em>Staphylococcus aureus</em> ATCC® 29213</th>
<th><em>Enterococcus faecalis</em> ATCC® 29212</th>
<th><em>Escherichia coli</em> ATCC® 25922</th>
<th><em>Pseudomonas aeruginosa</em> ATCC® 27853</th>
<th><em>Escherichia coli</em> ATCC® 35218&lt;sup&gt;b,c,g&lt;/sup&gt;</th>
<th><em>Klebsiella pneumoniae</em> ATCC® 700603&lt;sup&gt;b,g&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefepime-tazobactam&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1/8-4/8</td>
<td>-</td>
<td>0.03/8-0.12/8</td>
<td>0.5/8-4/8</td>
<td>-</td>
<td>0.12/8-0.5/8&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>Meropenem-vaborbactam&lt;sup&gt;t,u&lt;/sup&gt;</td>
<td>0.03/8-0.12/8</td>
<td>-</td>
<td>0.008/8-0.06/8</td>
<td>0.12/8-1/8</td>
<td>0.008/8-0.06/8</td>
<td>0.015/8-0.06/8</td>
</tr>
<tr>
<td>Tedizolid&lt;sup&gt;v&lt;/sup&gt;</td>
<td>0.12-1</td>
<td>0.25-1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vancomycin&lt;sup&gt;w&lt;/sup&gt;</td>
<td>0.5-2</td>
<td>1-4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Abbreviations: ATCC®, American Type Culture Collection; MIC, minimal inhibitory concentration.

#### Footnotes

- QC range for *K. pneumoniae* ATCC® BAA-1705™ with meropenem-vaborbactam is 0.015/8-0.06/8 µg/mL.
u. Test *S. aureus* ATCC® 29213 routinely when testing gram-positive organisms. Test *P. aeruginosa* ATCC® 27853 routinely when testing gram-negative organisms. Ranges are provided for other QC organisms as supplemental QC.

v. QC range for *S. aureus* ATCC® 25923 with tedizolid is 0.12–0.5 \( \mu g/mL \); this strain exhibits less trailing and MIC end points are easier to interpret. *S. aureus* ATCC® 25923 is considered a supplemental QC strain and not required for routine QC of tedizolid MIC tests.

w. For QC organisms for vancomycin screen test for enterococci, see Table 3G.

x. Cefepime-tazobactam (fixed 8 \( \mu g/mL \)) MIC QC ranges are for use with the cefepime-tazobactam high proportion (1:1 ratio) dosing regimen.

Table 5D:

In Table 5D, the ertapenem QC range for *Bacteroides thetaiotaomicron* ATCC® 29741 was incomplete. The range has been corrected from “0.25–” to “0.25–1.” This change is highlighted in the table excerpt below.

<table>
<thead>
<tr>
<th>Antimicrobial Agent</th>
<th><em>Bacteroides fragilis</em> ATCC® 25285</th>
<th><em>Bacteroides thetaiotaomicron</em> ATCC® 29741</th>
<th><em>Clostridium difficile</em> ATCC® 700057</th>
<th><em>Eggerthella lenta</em> (formerly <em>Eubacterium lentum</em>) ATCC® 43055b</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ertapenem</td>
<td>0.06–0.25</td>
<td>0.25–1</td>
<td>-</td>
<td>0.5–2</td>
</tr>
</tbody>
</table>

Abbreviations: ATCC®, American Type Culture Collection; MIC, minimal inhibitory concentration, QC, quality control.

Glossary II:

- The title has been corrected to reflect the current edition of M100: “M100, 27th ed.”
- The three-letter designation for cefepime-tazobactam has been changed from “FPZ” to “FPT.”

The Glossary II changes described above are highlighted in the glossary excerpt below.

Glossary II. Abbreviations/Routes of Administration/Drug Class for Antimicrobial Agents Listed in *M100, 27th ed.*

<table>
<thead>
<tr>
<th>Antimicrobial Agent</th>
<th>Agent Abbreviation</th>
<th>Routes of Administration</th>
<th>Drug Class or Subclass</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefepime-tazobactam</td>
<td>FPT</td>
<td>PO IM IV Topical</td>
<td>( \beta )-lactam/( \beta )-lactamase inhibitor</td>
</tr>
</tbody>
</table>

Abbreviations: PO, per OS (oral); IM, intramuscular; IV, intravenous.

If you require any additional clarification regarding these corrections, please contact CLSI Customer Service (customerservice@clsi.org).

We appreciate your commitment to CLSI, and regret any inconvenience.